Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Income from Continuing Operations (2019 - 2023)

Historic Income from Continuing Operations for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$45.3 million.

  • ADC Therapeutics' Income from Continuing Operations rose 1293.1% to -$45.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$153.5 million, marking a year-over-year decrease of 1131.47%. This contributed to the annual value of -$153522.0 for FY2022, which is 9993.14% up from last year.
  • Latest data reveals that ADC Therapeutics reported Income from Continuing Operations of -$45.3 million as of Q3 2023, which was up 1293.1% from -$48.2 million recorded in Q2 2023.
  • ADC Therapeutics' Income from Continuing Operations' 5-year high stood at -$16223.0 during Q4 2022, with a 5-year trough of -$126.3 million in Q2 2020.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$45.3 million (2023), whereas its average is -$39.8 million.
  • As far as peak fluctuations go, ADC Therapeutics' Income from Continuing Operations plummeted by 54544835.92% in 2020, and later skyrocketed by 9715.3% in 2022.
  • Over the past 5 years, ADC Therapeutics' Income from Continuing Operations (Quarter) stood at -$35055.0 in 2019, then tumbled by 57905.99% to -$20.3 million in 2020, then surged by 97.2% to -$569831.0 in 2021, then skyrocketed by 97.15% to -$16223.0 in 2022, then plummeted by 279145.52% to -$45.3 million in 2023.
  • Its last three reported values are -$45.3 million in Q3 2023, -$48.2 million for Q2 2023, and -$60.0 million during Q1 2023.